Abstract
Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme. Remarkably, we discovered IDO-specific T cells that can influence adaptive immune reactions in patients with cancer. Further, a recent phase I clinical trial demonstrated long-lasting disease stabilization without toxicity in patients with non-small-cell lung cancer (NSCLC) who were vaccinated with an IDO-derived HLA-A2-restricted epitope.
| Original language | English |
|---|---|
| Article number | e983770 |
| Journal | OncoImmunology |
| Volume | 4 |
| Issue number | 1 |
| Pages (from-to) | 1-3 |
| Number of pages | 3 |
| ISSN | 2162-4011 |
| DOIs | |
| Publication status | Published - 2 Jan 2015 |
